A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer

NCT07241767 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin
DRUG: FH-006 ; SHR-1316 ; BP102
DRUG: FH-006; SHR-1316 ; SHR-8068

Sponsor

Jiangsu HengRui Medicine Co., Ltd.